Connect Sign InPBM in Hematology Oncology
Transfusions play an essential role in the treatment provided to hematology and oncology patients. Guidelines for transfusing hospitalized hematology and oncology patients are similar to those for other patient populations; however, these patients often receive repeat transfusions and are therefore at risk for transfusion-related complications (e.g., alloimmunization, refractoriness, and delayed hemolytic transfusion reactions). This presentation addresses red blood cell, platelet, and granulocyte transfusions for these patients. Additionally, it discusses investigations seeking correlations of blood donor and blood component preparation technologies with patient outcomes.
Originally presented at the University of Utah Department of Pathology Patient Blood Management Master Class during May 2025.
Jay Menitove, MD, former CEO and medical director of the Community Blood Center of Greater Kansas City, is a clinical professor of Pathology and Laboratory Medicine at the Kansas University Medical Center. He is board certified in internal medicine, hematology, and blood banking. He serves as an associate editor of Transfusion, chaired the HHS Advisory Committee on Blood and Tissue Safety and Availability, and was a past president of Association for the Advancement of Blood & Biotherapies (AABB). Dr. Menitove’s academic interests include transfusion safety, blood donation, and sustainability of the U.S. blood supply system. He is the author or coauthor of more than 160 journal articles, textbook chapters, and other publications.
